EGFR and cancer: Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-OH kinase (PI3K) emerge as potential cotargeting candidates to test this concept because these oncogenic kinases drive adaptive resistance across a broad spectrum of human cancers.